References
- Nordestgaard BG, Langlois MR, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46–61.
- McNeal CJ. Lipoprotein(a): its relevance to the pediatric population. J Clin Lipidol. 2015;9(5 Suppl):S57–S66.
- Saeedi R, Li M, Allard M, et al. Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol. Clin Biochem. 2014;47(12):1098–1099.
- Li KM, Wilcken DEL, Dudman NPB. Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the friedewald formula. Clin Chem. 1994;40(4):571–573.
- Kronenberg F, Lingenhel A, Lhotta K, et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int. 2004;66(1):348–354.
- Fatica EM, Meeusen JW, Vasile VC, et al. Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. Clin Biochem. 2020;86:45–51.
- Dahlen GH. Incidence of Lp(a) among populations. In: Scanuu AM, editor. Lipoprotein(a). New York: Academic Press; 1990. p. 151–173.
- Pang J, Chan DC, Watts GF. The knowns and unknowns of contemporary statin therapy for familial hypercholesterolemia. Curr Atheroscler Rep. 2020;22(11):64.
- Scanu AM, Hinman J. Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein (a) levels. Lipids. 2002;37(5):439–444.
- Hernández C, Francisco G, Ciudin A, et al. Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial. Diabetes Metab. 2011;37(2):124–130.
- Wang X, Li J, Ju J, et al. Effect of different types and dosages of statins on plasma lipoprotein(a) levels: a network meta-analysis. Pharmacol Res. 2021;163:105275.
- Tsimikas S, Gordts PLSM, Nora C, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275–2284.
- Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of Rosuvastatin versus Atorvastatin, Simvastatin, and Pravastatin across doses (STELLAR* trial). Am J Cardiol. 2003;92(2):152–160.
- Enas EA, Varkey B, Dharmarajan TS, et al. Lipoprotein(a): an independent, generic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J. 2019;71(2):99–112.
- Vavuranakis MA, Jones SR, Cardoso R, et al. The role of Lipoprotein(a) in cardiovascular disease: current concepts and future perspectives. Hellenic J Cardiol. 2020;61(6):398–403.
- Sahebkar A, Simental-Mendía LE, Pirro M, et al. Impact of ezetimibe on plasma liporptein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):17887.
- Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein (a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053.
- Guadagno PA, Summers Bellin EG, Harris WS, et al. Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. Clin Chim Acta. 2015;439:219–224.